HIGHLIGHTS Q3 2025 ~$401.4 million in cash and cash equivalents Drawn ~$137.2 million under the US$450 million Appian financing facility executed during the quarter Completed private placements for ...
WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, ...
All brelovitug dose regimens studied were well tolerated Results will be presented at The Liver Meeting® 2025 of AASLD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback